Stifel cuts Boston Scientific stock price target on EP data review

Stifel lowered its price target for Boston Scientific Corp. (NYSE:BSX) to $85 from $90, while maintaining a Buy rating. The adjustment was based on monthly electrophysiology hospital-purchasing data and recent company commentary, ahead of the company’s Q1 2026 earnings report. Despite a recent unmet expectation in a heart implant trial, other analysts like UBS, Truist Securities, Piper Sandler, and RBC Capital have largely maintained positive ratings, albeit some with adjusted price targets.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin